$BLTE News

Morgan Stanley Maintains Overweight on Belite Bio, Raises Price Target to $206

Cantor Fitzgerald Maintains Overweight on Belite Bio, Raises Price Target to $270

Belite Bio, Inc (BLTE) Q2 2026 Earnings Call Transcript

Full Transcript: Belite Bio Q2 2026 Earnings Call

Belite Bio Q2 Adj. EPS $(0.54) Beats $(0.79) Estimate

HC Wainwright & Co. Maintains Buy on Belite Bio, Raises Price Target to $214

Belite Bio: The Oral Route Is The Real Competitive Moat

Why Is Belite Bio Stock Gaining Monday?

Belite Bio Announces Additional Secondary Endpoint Data From Phase 3 DRAGON Trial Of Tinlarebant In Stargardt Disease, Presented At ASRS 2026 In Montréal

HC Wainwright & Co. Reiterates Buy on Belite Bio, Maintains $200 Price Target

Belite Bio, Inc (BLTE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Full Transcript: Belite Bio Q1 2026 Earnings Call

Belite Bio, Inc (BLTE) Presents at 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026) - Slideshow

Mizuho Maintains Outperform on Belite Bio, Lowers Price Target to $215

Belite Bio, Inc 2026 Q1 - Results - Earnings Call Presentation

HC Wainwright & Co. Reiterates Buy on Belite Bio, Maintains $200 Price Target

Belite Bio, Inc (BLTE) Q1 2026 Earnings Call Transcript

Belite Bio Q1 EPS $(0.45) Beats $(0.63) Estimate

Belite Bio's Tinlarebant Receives Orphan Drug Status From Swiss Agency For Therapeutic Products To Treat Stargardt Disease

Belite Bio To Present Topline Data From Phase 3 DRAGON Study Of Stargardt Disease Type 1 Treatment At 27th Fundus Disease Forum And International Retinal Symposium